Ferring Pharmaceuticals has secured the rights to a Phase III treatment of radicular leg pain outside of Japan from Seikagaku.

Since Celyad failed to reach its primary endpoints in a stem cell therapy test in heart patients back in June, CardioCell has felt the pressure to deliver and…

Sofinnova Ventures, which over the course of its now ten funds has evolved its focus from early-stage life science and tech firms to later stage biotechs, has…

Medivation loses its VP after the Pfizer buy, Shanghai Pharma loses its chairman after only three months and Sarah Jessica Parker waves goodbye to Mylan…

Struggling microcap GenVec has again been warned that it will be taken off the lucrative and respected Nasdaq exchange if it doesn’t get itself out of the…

Adocia has cut loose its diabetic foot ulcer program after the drug failed a Phase III trial.

Novartis has hit the primary endpoint in what it says is the largest randomized, controlled study to date to treat secondary progressive multiple sclerosis…

Investors have plowed another $130 million into a Series B to back the startup that’s led by Genentech vets, which brings its total raised to almost $350…